The paper presents the results of three bioequivalence studies on DlyaZhens metri (dienogest), DlyaZhens pro (progesterone), DlyaZhens klimo (levonorgestrel + estradiol) manufactured by the “Farmasintez-Tyumen” LLC, Russia, and their corresponding original (reference) drugs Visanne (Bayer Pharma AG, Germany), Utrogestan (Besen Healthcare SA, Belgium), and Klimonorm (Jenapharm GmbH & Co. KG, Germany). The bioequivalence studies determined the pharmacokinetic parameters of dienogest, progesterone, and levonorgestrel + estradiol in the plasma of healthy volunteers after single oral dose intake of the compared drugs during fasting according to a 2-stage open-label randomized crossover regimen for dienogest and levonorgestrel + estradiol and according to 4-stage one for progesterone. The plasma concentration of the active ingredients of the drugs was analyzed by a highly sensitive and selective bioanalytical method using high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). The following pharmacological parameters (AUC0-t, AUC0-∞, AUC0-72, AUCresid, AUCresid%, Cmax, TСmax, T½, kel, f’, Cmax/AUC, MRT) were calculated for the drugs analyzed. The 90% confidence intervals for the ratios of the geometric mean values of AUC0-t and Cmax were in the range from 80.00 to 125.00% in the bioequivalence studies of dienogest, progesterone, and levonorgestrel + estradiol. Conclusion: The findings have led to the conclusions about the bioequivalence of the test and reference drugs, such as dienogest, progesterone, and levonorgestrel + estradiol. The safety profiles of the compared drugs were comparable.